Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), MR antagonists(Mineralocorticoid receptor antagonists), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H22N4O3 |
InChIKeyBTBHLEZXCOBLCY-QGZVFWFLSA-N |
CAS Registry1050477-31-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiomyopathies | Phase 2 | US | 11 Mar 2024 | |
Diabetes Mellitus, Type 2 | Phase 2 | US | 11 Mar 2024 | |
Heart Failure | Phase 2 | US | 11 Mar 2024 | |
Hypertension | Phase 2 | US | 11 Mar 2024 |